Media coverage about TherapeuticsMD (NASDAQ:TXMD) has trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. TherapeuticsMD earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.952528311259 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media headlines that may have impacted Accern’s scoring:
- TherapeuticsMD (TXMD) Upgraded at ValuEngine (americanbankingnews.com)
- The Markets Are Undervaluing these stock’s: TherapeuticsMD, Inc., (NASDAQ: TXMD), PBF Energy Inc., (NYSE: PBF); (tradingnewsnow.com)
- Enrapturing Stocks: TherapeuticsMD, Inc., (NASDAQ: TXMD), The Goldman Sachs Group, Inc., (NYSE: GS) (globalexportlines.com)
- Have you thought to include Oversold stock in Portfolio? TherapeuticsMD, Inc. (TXMD) (nasdaqchronicle.com)
- TherapeuticsMD Announces Expansion of Board of Directors (finance.yahoo.com)
Several analysts recently weighed in on TXMD shares. Oppenheimer set a $10.00 price objective on TherapeuticsMD and gave the company a “buy” rating in a research note on Wednesday, February 21st. BidaskClub downgraded TherapeuticsMD from a “sell” rating to a “strong sell” rating in a research report on Friday, February 23rd. Cantor Fitzgerald reiterated a “buy” rating and issued a $28.00 target price on shares of TherapeuticsMD in a research report on Sunday, January 7th. Zacks Investment Research downgraded TherapeuticsMD from a “hold” rating to a “sell” rating in a research report on Friday, January 12th. Finally, Noble Financial reaffirmed a “buy” rating on shares of TherapeuticsMD in a research note on Thursday, February 22nd. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $14.50.
TherapeuticsMD (NASDAQ:TXMD) last issued its earnings results on Tuesday, February 20th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.01). TherapeuticsMD had a negative net margin of 458.49% and a negative return on equity of 63.67%. The firm had revenue of $4.13 million during the quarter, compared to the consensus estimate of $4.66 million. During the same quarter in the previous year, the firm earned ($0.12) earnings per share. The business’s quarterly revenue was down 8.0% compared to the same quarter last year. research analysts anticipate that TherapeuticsMD will post -0.38 EPS for the current fiscal year.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.